Literature DB >> 12162707

Pharmacokinetic characterization of 14C-vascular endothelial growth factor controlled release microspheres using a rat model.

Tae-Kyoung Kim1, Diane J Burgess.   

Abstract

The objectives of this study were to characterize the pharmacokinetics of vascular endothelial growth factor (VEGF) in poly(lactic-co-glycolic) acid (PLGA) microspheres using a rat model, and to develop a pharmacokinetic model for this controlled release formulation. 14C-VEGF was encapsulated using a solid-in-oil-in-water emulsification method. The microspheres were administered subcutaneously to rats and the pharmacokinetic parameters were compared with those of protein solutions. Intravenous administration of protein solutions resulted in short half-lives and subcutaneous administration resulted in rapid clearance from the subcutaneous tissue, with high plasma concentrations as expressed by rapid absorption and elimination. The subcutaneous administration of the VEGF microspheres produced low plasma concentrations and high subcutaneous concentrations over a period of 7 weeks. The area under the curve (AUC), the time required to achieve the maximum concentration (tmax), the maximum concentration (Cmax) in blood samples and the elimination rate constant (kel) values at the subcutaneous tissue site were selected to compare the pharmacokinetic characterization of VEGF microspheres with that of protein solutions. The in-vivo release profiles of the proteins were slower than the in-vitro release profiles and they followed the same trend as the in-vitro and in-vivo PLGA degradation rates. The PLGA microsphere degradation was the determinant step for VEGF release from the microspheres and its absorption at the subcutaneous site. Microspheres appear to be an attractive system for the localized rate-controlled delivery of VEGF. 14C-Methylation via reductive alkylation of VEGF did not affect its mitogenic activity, however approximately 25% activity was lost following release from PLGA microspheres. This loss of activity may be due to degradation in an acidic environment as a result of PLGA degradation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12162707     DOI: 10.1211/002235702760089009

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  12 in total

Review 1.  Technologies for continuous glucose monitoring: current problems and future promises.

Authors:  Santhisagar Vaddiraju; Diane J Burgess; Ioannis Tomazos; Faquir C Jain; Fotios Papadimitrakopoulos
Journal:  J Diabetes Sci Technol       Date:  2010-11-01

2.  Biomimetic delivery of keratinocyte growth factor upon cellular demand for accelerated wound healing in vitro and in vivo.

Authors:  David J Geer; Daniel D Swartz; Stelios T Andreadis
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

Review 3.  Biocompatible materials for continuous glucose monitoring devices.

Authors:  Scott P Nichols; Ahyeon Koh; Wesley L Storm; Jae Ho Shin; Mark H Schoenfisch
Journal:  Chem Rev       Date:  2013-02-07       Impact factor: 60.622

4.  Engineering of multifunctional gels integrating highly efficient growth factor delivery with endothelial cell transplantation.

Authors:  Steven M Jay; Benjamin R Shepherd; James P Bertram; Jordan S Pober; W Mark Saltzman
Journal:  FASEB J       Date:  2008-05-01       Impact factor: 5.191

5.  In vitro/in vivo correlation for 14C-methylated lysozyme release from poly(ether-ester) microspheres.

Authors:  R van Dijkhuizen-Radersma; S J Wright; L M Taylor; B A John; K de Groot; J M Bezemer
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

6.  A review of the development of a vehicle for localized and controlled drug delivery for implantable biosensors.

Authors:  Upkar Bhardwaj; Fotios Papadimitrakopoulos; Diane J Burgess
Journal:  J Diabetes Sci Technol       Date:  2008-11

7.  Cell-responsive hydrogel for encapsulation of vascular cells.

Authors:  Thomas P Kraehenbuehl; Lino S Ferreira; Prisca Zammaretti; Jeffrey A Hubbell; Robert Langer
Journal:  Biomaterials       Date:  2009-06-04       Impact factor: 12.479

8.  Recombinant human VEGF165b protein is an effective anti-cancer agent in mice.

Authors:  Emma S Rennel; Maryam A Hamdollah-Zadeh; Edward R Wheatley; Anette Magnussen; Yvonne Schüler; Sara P Kelly; Ciara Finucane; David Ellison; Stephanie Cebe-Suarez; Kurt Ballmer-Hofer; Stephen Mather; Lorna Stewart; David O Bates; Steven J Harper
Journal:  Eur J Cancer       Date:  2008-07-24       Impact factor: 9.162

9.  A differential effect of bone morphogenetic protein-2 and vascular endothelial growth factor release timing on osteogenesis at ectopic and orthotopic sites in a large-animal model.

Authors:  Ruth E Geuze; Lars F H Theyse; Diederik H R Kempen; Herman A W Hazewinkel; Helen Y A Kraak; F Cumhur Oner; Wouter J A Dhert; Jacqueline Alblas
Journal:  Tissue Eng Part A       Date:  2012-09-12       Impact factor: 3.845

10.  Controlled delivery of VEGF via modulation of alginate microparticle ionic crosslinking.

Authors:  Steven M Jay; W Mark Saltzman
Journal:  J Control Release       Date:  2008-11-08       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.